Literature DB >> 10206086

The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.

R Heinig1, H G Adelmann, G Ahr.   

Abstract

OBJECTIVE: The primary aim of the present study was to investigate the effect of ketoconazole on the pharmacokinetics of nisoldipine.
METHODS: A single dose of nisoldipine 5 mg immediate-release tablet was administered either alone or in combination with ketoconazole 200 mg (4 days pretreatment and concomitant administration) in a randomized crossover trial in seven healthy male Caucasian volunteers. Plasma concentration-versus-time profiles of nisoldipine and its metabolite M9 were determined.
RESULTS: Pre-treatment with and concomitant administration of ketoconazole resulted in a 24-fold and 11-fold, increase in mean AUC and Cmax of nisoldipine, respectively, compared with treatment with nisoldipine 5 mg alone. The ketoconazole-induced increase in plasma concentration of the metabolite M9 was of similar magnitude.
CONCLUSION: The interaction is attributed to inhibition of cytochrome 3A4-mediated first-pass metabolism. Ketoconazole and other antifungal drugs of the substituted imidazole type as well as other potent inhibitors of cytochrome 3A4 should not be used concomitantly with nisoldipine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206086     DOI: 10.1007/s002280050593

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

Authors:  Paul L M van Giersbergen; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

4.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.

Authors:  Gilbert Lefèvre; Polly Carpenter; Claire Souppart; Heinz Schmidli; Mark McClean; Daria Stypinski
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

5.  General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects.

Authors:  Pratapa P Prasad; Daria Stypinski; Kunjbala H Vyas; Leonard Gonasun
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

7.  A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.

Authors:  Akihiro Hisaka; Makiko Kusama; Yoshiyuki Ohno; Yuichi Sugiyama; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.